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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to an urgent 
need for vaccines, particularly among persons at high 
risk for severe disease and death, such as the elderly 
(1). Effi cacy against severe coronavirus disease (COV-
ID-19) of mRNA vaccine BNT162b2 (Pfi zer-BioNTech, 
https://www.pfi zer.com) is reported to be >90% 
starting 7 days after the second vaccination; robust 
antibody and T-cell response has been demonstrated
consistently across age groups (2–4). However, only 
4.3% of participants in the BNT162b2 effi cacy trial 
were >75 years of age (4). Given the elderly generally 
have weaker immune responses after vaccination, 
more detailed investigation is necessary (4,5).
The Study
In a prospective observational cohort study, we in-
vestigated SARS-CoV-2–specifi c antibodies, matura-
tion of IgG avidity, and interferon-γ (IFN-γ) release 
of SARS-CoV-2–specifi c T cells in 2 cohorts of young 
and elderly BNT162b2-vaccinated persons (Table). 
Participants were recruited from 2 studies conducted 
at Charité–Universitätsmedizin Berlin, both conduct-
ed in accordance with the Declaration of Helsinki and 
Good Clinical Practice (https://www.ema.europa.
eu/en/documents/scientific-guideline/ich-e-6-r2-
guideline-good-clinical-practice-step-5_en.pdf) and 
approved by the local ethics committee (EA4/244/20 
and EA4/245/20)
The fi rst cohort consisted of 123 healthcare work-
ers; median age was 34 (interquartile range [IQR] 20–64) 
years. The second cohort consisted of 71 elderly resi-
dents of an assisted living facility; median age was 81 
(IQR 70–96) years. Blood samples were taken before the 
fi rst vaccination (week 0), just before the second vacci-
nation (week 3), and 4 weeks after the second vaccina-
tion (week 7). To discriminate between vaccine-induced 
antibody response and convalescent SARS-CoV-2 
infection, we used the SeraSpot Anti-SARS-CoV-2 
IgG microarray-based immunoassay including nu-
cleocapsid and spike as antigens (Seramun Diagnos-
tica GmbH, https://www.seramun.com) (Appendix, 
https://wwwnc.cdc.gov/EID/article/27/8/21-1145-
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coronavirus	 disease	 remain	 crucial	 and	 that	 additional	
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App1.pdf). Ten of 123 healthcare workers and 1 of 71 
elderly participants showed reactive anti-nucleocapsid 
or anti-spike IgG before the first vaccination and were 
excluded from further analyses.
At week 3, in the younger cohort, 93/107 (86.9%, 
95% CI 79.2%–92.0%) participants showed reac-
tive SARS-CoV-2 receptor-binding domain (RBD) 
IgG, compared with only 16/52 elderly participants 
(30.8%, 95% CI 19.9%–44.3%). At week 7, the anti-
body response rate had increased in both cohorts, 
to 112/113 in younger participants (99.1%, 95% CI 
95.2%–100.0%) and 64/70 in the elderly cohort (91.4%, 
95% CI 82.5%–96.0%) (Figure, panel A; Appendix Ta-
ble). The comparison of SARS-CoV-2 RBD IgG levels 
demonstrated a significant difference in the 2 cohorts 
at both week 3 (p<0.0001) and week 7 (p = 0.0003) 
(Appendix Table), indicating a substantial delay and 
overall reduced antibody response in elderly partici-
pants. We observed similar kinetics and differences 
between cohorts for antibody responses to 2 further 
SARS-CoV-2 spike antigens: the S1 subdomain and 
the full spike protein (Appendix Table, Figure).
We further confirmed the delayed and reduced 
antibody response in the elderly by measurement of 
the functional neutralization capacity using the sur-
rogate virus neutralization test (sVNT) cPass (medac 
GmbH, https://international.medac.de) (Appen-
dix) (6). At week 3, only 24/52 elderly participants 
(46.2%, 95% CI 33.3%–59.5%) had neutralizing ca-
pacity in serum, compared with 97/107 younger 
participants (90.7%, 95% CI 83.7%–94.8%; p<0.0001 
(Figure). In addition, the median sVNT titer for el-
derly participants was significantly lower than the 
young cohort (26.4% [IQR 6.8%–40.9%] vs. 60.2% 
[IQR 45.0%–76.4%]; p<0.0001) (Appendix Table). 
Although the neutralizing antibody response rate 
increased to 63/70 (90.0%, 95% CI 80.8%–95.1%) in 
elderly participants by week 7, the median sVNT ti-
ter remained significantly lower than in the younger 
cohort (89.6% [IQR 70.9%–95.2%] vs. 96.7% [IQR 
95.6%–97.2%]; p<0.0001) (Appendix Table).
To characterize the maturation of IgG avidity 
in all 16 elderly and 30 randomly selected younger 
participants who were seroreactive at week 3, we 
applied a modified SARS-CoV-2 S1 IgG ELISA (Eu-
roimmun, https://www.euroimmun.com) (Appen-
dix Figure 2). The delayed antibody response in the 
elderly is reflected in results: at week 7, only 8/16 
elderly (50.0%, 95% CI 28.0%–72.0%) exhibited high 
S1 IgG avidity indices (>60) compared with 28/30 
young participants (93.3%, 95% CI 78.7%–98.8%) 
(Figure, panel C). Consequently, the median rela-
tive avidity index of IgG was significantly higher in 
the younger cohort than the elderly cohort (76.2% 
[IQR 67.6%–82.9%] vs. 59.3% [IQR 55.3%–68.9%]; p 
= 0.0002) (Figure, panel C).
In addition to antibody responses, we assessed 
SARS-CoV-2 spike-specific T cell responses by an 
IFN-γ release assay (IGRA) (Euroimmun) (Appendix) 
of S1 peptide-stimulated T cells at week 7. The pro-
portion of persons with IGRA results above the de-
fined threshold (Appendix) was significantly lower in 
the elderly than in younger participants (51.2% [95% 
CI 36.8%–65.4%] vs. 84.5% [95% CI 74.4%–91.1%]; p 
= 0.0002). Accordingly, median S1-induced IFN-γ 
release was significantly decreased in the elderly 
compared to younger participants (707.3 mIU/mL 
[IQR 216–1,392] vs. 2184 mIU/mL [IQR 1,274–2,484]; 
p<0.0001) (Figure, panel D). In contrast, we detected 
no significant difference in IFN-γ release after mito-
gen stimulation between the 2 cohorts, indicating no 
general impairment of IFN-γ responses in the elderly 
(p = 0.77) (Figure, panel D; Appendix Table).
In summary, vaccination with BNT162b2 induces 
both arms of adaptive immunity: SARS-CoV-2–spe-
cific antibodies and SARS-CoV-2–specific T cells. 
However, we observed delayed and less robust cel-
lular and humoral immune response among the el-
derly than among younger adults. A limitation of our 
study is the lack of data on other COVID-19 vaccines. 
Furthermore, we cannot exclude that underlying dis-








No.	patients 123 71 
Sex 
    
 F 65	(52.9) 54	(76.1) 
 M 58	(47.2) 17	(23.9) 
Median	age,	y	(IQR) 34	(20–64) 81	(70–96) 
Underlying	conditions 
    
 Cardiovascular	disease 15	(12.2) 56	(78.9) 
 Type	2	diabetes 1	(0.8) 13	(18.3) 
 Respiratory	disease 16	(13.0) 11	(15.5) 
 Dyslipidemia 5	(4.1) 21	(29.6) 
 Thyroid	dysfunction 0 16	(22.5) 
 Chronic	kidney	disease 0 12	(16.9) 
 Chronic	liver	or	GI	disease 2	(1.6) 18	(25.4) 
 Rheumatic	disease 6	(4.9) 7	(9.9) 
 Active	solid	malignancy 2	(1.6) 4	(5.6) 
 Active	hematological	malignancy 0 4	(5.6) 
 Neurologic	disease 1	(0.8) 18	(25.4) 
 Immunodeficiency 1	(0.8) 0 
 Others 9	(7.3) 29	(40.9) 
Outpatient	medication 
    
 No 79	(64.2) 5	(7.0) 
 Yes 39	(31.7) 64	(90.1) 






elderly (Table), might impair the vaccine-induced 
immune response. For example, patients on dialy-
sis have significantly lower antibody response than 
vaccinated same-age patients not on dialysis (E. 
Schrezenmeier et al., unpub. data, http://medrxiv.
org/lookup/doi/10.1101/2021.03.31.21254683).
Our data are supported by other real-world obser-
vations suggesting a delayed and reduced immunoge-
nicity of BNT162b2 in the elderly (5,7; D.A. Collier et al., 
unpub. data, http://medrxiv.org/lookup/doi/10.110
1/2021.02.03.21251054). In line with our observations 
for BNT162b2, an effect of age-dependent decrease of 
immune function, referred to as immunosenescence, is 
well known and contributes to increased prevalence of 
infectious disease and vaccine failure in the elderly (8). 
A lower vaccine-induced immune response to influ-
enza and hepatitis B viruses is well documented (9,10); 
however, such data are scarce for mRNA vaccines.
Of note, vaccination with 2 doses of BNT162b2 
might not fully prevent SARS-CoV-2 outbreaks 
among elderly persons in congregate settings, such as 
long-term care facilities, possibly because of delayed 
and reduced immune response. However, vaccina-


















Although the immune response of elderly partici-
pants 4 weeks after the second dose of BNT162b2 
nearly reached the level of younger participants, a 
small fraction of elderly participants did not demon-
strate robust antibody and T-cell response. Howev-
er, the immunologic correlates of protection remain 
unknown, and identification of persons with no or 
incomplete protection after vaccination remains chal-
lenging. Therefore, strategies focused solely on vac-
cinating high-risk groups might be insufficient to pro-
tect those at risk for severe disease. For the elderly, 
vaccinating caregivers and close contacts should be 
prioritized. Moreover, a booster vaccination, altered 
vaccine dose, or different COVID-19 vaccines should 
be considered for the elderly if further evidence dem-
onstrates high rates of breakthrough infections de-
spite 2-dose BNT162b2 vaccination.
These results are particularly relevant for vacci-
nation strategies focused on broad administration of 
the first dose of a 2-dose vaccine while postponing the 
second vaccination. This practice might leave a rel-
evant proportion of elderly with comparatively low 
levels of immunity for a prolonged period, empha-
sizing the need for nonpharmaceutical interventions, 
such as mask use and regular testing.
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